U.S. biotech giant Regeneron chooses Hyderabad to set up GCC
Regeneron Pharmaceuticals Inc. is set to establish a global capability center in Hyderabad, aiming to enhance its global operations. The center is expected to be operational by the second half of 2026 and will create hundreds of jobs as it expands. Hyderabad's reputation as a hub for life sciences and technology talent is a key factor in Regeneron's decision to invest in the region.
- ▪Regeneron Pharmaceuticals Inc. plans to establish its global capability center in Hyderabad.
- ▪The center will be operational in the second half of 2026 and is expected to create hundreds of jobs.
- ▪Hyderabad currently hosts nearly 450 global capability centers and continues to attract international investments.
The Hindu — Top publishes from India and files mainly under world. We currently carry 7,843 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Hindu — Top |
| Canonical URL | https://www.thehindu.com/news/cities/Hyderabad/us-biotech-giant-regeneron-chooses-hyderabad-to-set-up-gcc/article71025562.ece |
| Publication time | Tue, 26 May 2026 19:38:58 +0530 |
| Retrieval time | 2026-05-26T14:17:49.694Z |
| Last seen | 2026-05-26T14:17:49.694Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | C-bV-qgdzfsd |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
U.S. biotechnology firm Regeneron Pharmaceuticals Inc. plans to establish its global capability centre (GCC) in Hyderabad.It is a strategic investment decision to deepen global operations and scale business functions. The Regeneron GCC will be operational in the second half of 2026 and is expected to grow to hundreds of jobs in the coming years as it expands capabilities across key global functions, the global biotechnology leader said.The company has 15 approved or authorised medicines and nearly 50 pipeline candidates spanning multiple therapeutic areas and is supported by more than 15,000 employees across North America, Europe and Asia.“Hyderabad has established itself as a world-class hub for Life Sciences and technology talent and we are proud to expand our presence there.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu — Top.
Discussion
0 commentsMore from The Hindu — Top
